Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biohaven Ltd. stock logo
BHVN
Biohaven
$12.35
-9.5%
$13.42
$8.03
▼
$18.24
$1.87B1.362.75 million shs1.93 million shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$6.90
-5.6%
$11.25
$2.08
▼
$15.37
$3.19B0.8815.56 million shs11.24 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$93.82
+0.3%
$83.53
$37.02
▼
$99.31
$7.37B0.07697,172 shs414,489 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$286.87
0.0%
$302.30
$175.89
▼
$326.63
$5.74B1.16263,654 shs169,474 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biohaven Ltd. stock logo
BHVN
Biohaven
+5.42%-3.03%+15.32%-2.05%+44.07%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-2.27%-4.19%-50.81%-11.82%+223.45%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-1.59%-2.85%+12.47%+18.36%+121.87%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-3.94%-9.27%-6.35%+0.23%+39.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biohaven Ltd. stock logo
BHVN
Biohaven
$12.35
-9.5%
$13.42
$8.03
▼
$18.24
$1.87B1.362.75 million shs1.93 million shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$6.90
-5.6%
$11.25
$2.08
▼
$15.37
$3.19B0.8815.56 million shs11.24 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$93.82
+0.3%
$83.53
$37.02
▼
$99.31
$7.37B0.07697,172 shs414,489 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$286.87
0.0%
$302.30
$175.89
▼
$326.63
$5.74B1.16263,654 shs169,474 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biohaven Ltd. stock logo
BHVN
Biohaven
+5.42%-3.03%+15.32%-2.05%+44.07%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-2.27%-4.19%-50.81%-11.82%+223.45%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-1.59%-2.85%+12.47%+18.36%+121.87%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-3.94%-9.27%-6.35%+0.23%+39.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biohaven Ltd. stock logo
BHVN
Biohaven
2.60
Moderate Buy$22.5782.71% Upside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.71
Moderate Buy$13.80100.00% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
2.80
Moderate Buy$102.389.12% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
2.89
Moderate Buy$355.3823.88% Upside

Current Analyst Ratings Breakdown

Latest BHVN, IOVA, LGND, and KNSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/19/2026
Biohaven Ltd. stock logo
BHVN
Biohaven
Boost Price TargetOverweight$14.00 ➝ $35.00
11/17/2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Boost Price TargetBuy$100.00 ➝ $115.00
11/11/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Boost Price TargetOverweight$345.00 ➝ $350.00
11/6/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetOverweight$18.00 ➝ $19.00
11/6/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetMarket Outperform$8.00 ➝ $12.00
11/5/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Boost Price TargetBuy$397.00 ➝ $402.00
11/3/2026
Biohaven Ltd. stock logo
BHVN
Biohaven
Boost Price TargetOverweight$19.00 ➝ $21.00
11/3/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetNeutral$7.00 ➝ $8.00
11/2/2026
Biohaven Ltd. stock logo
BHVN
Biohaven
UpgradeSell (E+) ➝ Sell (D-)
11/2/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
DowngradeBuy (B) ➝ Hold (C)
10/30/2026
Biohaven Ltd. stock logo
BHVN
Biohaven
Boost Price TargetBuy$21.00 ➝ $32.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A($0.65) per shareN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$378.98M8.42N/AN/A$1.76 per share3.92
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$677.56M10.88$0.78 per share119.75$9.04 per share10.38
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$268.09M21.40$7.54 per share38.04$48.08 per share5.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biohaven Ltd. stock logo
BHVN
Biohaven
-$738.82M-$3.86N/AN/AN/AN/A-2,271.88%-139.84%N/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$390.98M-$0.53N/AN/AN/A-58.20%-29.71%-23.55%N/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$59.01M$1.3072.1762.13N/A11.58%17.27%12.64%N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$124.45M$2.24128.0735.505.2220.27%5.22%2.74%N/A

Latest BHVN, IOVA, LGND, and KNSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.09-$0.05+$0.04-$0.05$115.98 million$121.47 million
10/29/2026Q3 2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$2.33$2.67+$0.34-$1.43$77.00 million$78.75 million
10/27/2026Q3 2026
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.3710$0.56+$0.1890$0.56$260.66 million$285.97 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biohaven Ltd. stock logo
BHVN
Biohaven
21.23
3.05
3.05
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
5.20
4.67
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.91
3.35
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.71
1.22
1.19
CompanyEmployeesShares OutstandingFree FloatOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
274151.06 million130.21 millionOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
975462.66 million426.57 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
36678.57 million37.73 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4720.00 million18.88 millionOptionable

Recent News About These Companies

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $350.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biohaven stock logo

Biohaven NYSE:BHVN

$12.35 -1.30 (-9.49%)
Closing price 03:59 PM Eastern
Extended Trading
$12.39 +0.04 (+0.29%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$6.90 -0.41 (-5.61%)
Closing price 03:59 PM Eastern
Extended Trading
$6.90 0.00 (0.00%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$93.82 +0.28 (+0.30%)
Closing price 03:58 PM Eastern
Extended Trading
$93.89 +0.07 (+0.08%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$286.87 -0.07 (-0.02%)
Closing price 03:59 PM Eastern
Extended Trading
$287.22 +0.35 (+0.12%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.